Biogen seeks US approval for potential Alzheimer's drug, stock jumps

Topics Biogen | Alzheimer's | Nasdaq

Biogen Inc said on Wednesday it submitted an application seeking US approval of its closely watched Alzheimer's drug, as the company aims to be the first to bring a treatment to market that can alter the course of the mind-wasting disease. Biogen shares were up nearly 5 per cent at $281.

34 in afternoon trading on the Nasdaq. The number of people in the United States living with Alzheimer's, the most common form of dementia, is expected to triple to nearly 14 million by 2050 without effective treatments, according to the.

This article is no longer available in our repository.

There could be multiple reasons for this.